Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1[ALX0081]----1件: 64 💬
2[SHP 655 (BAX 930)]----1件: 64 💬
3[TAK-755 orBAX930 or SHP655]----1件: 64 💬
4Acetate1件: Acetate---52件: 1, 2, 6, 10, 11, 13, 22, 35, 40, 46, 49, 51, 60, 63, 64, 65, 66, 67, 70, 71, 73, 75, 76, 77, 78, 79, 81, 83, 85, 86, 88, 89, 90, 96, 97, 113, 145, 156, 158, 162, 171, 206, 222, 223, 224, 225, 227, 235, 251, 265, 298, 299 💬
5ALX-0081----1件: 64 💬
6ALX0081----1件: 64 💬
7Anfibatide1件: Anfibatide---1件: 64 💬
8Anti-CD20 antibody----2件: 13, 64 💬
9Anti-von Willebrand Factor Nanobody----1件: 64 💬
10Anti-von Willebrand Factor Nanobody, Caplacizumab1件: Caplacizumab1件: Caplacizumab 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
11Anti-von Willebrand Factor Nanobody, INN = Caplacizumab1件: Caplacizumab1件: Caplacizumab 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
12Apadamtase alfa1件: Apadamtase alfa2件: Apadamtase alfa ,
Apadamtase alfa and cinaxadamtase alfa 💬 		1件: ADAMTS13 💬 1件: Platelet activation 💬1件: 64 💬
13Apademtase alfa----1件: 64 💬
14ARC 1779----1件: 64 💬
15ARC1779----1件: 64 💬
16ARC1779 Injection----1件: 64 💬
17Aspirin tablet----1件: 64 💬
18BAX930----1件: 64 💬
19BAX930 - RECOMBINANT HUMAN ADAMTS131件: Apadamtase alfa2件: Apadamtase alfa ,
Apadamtase alfa and cinaxadamtase alfa 💬 		1件: ADAMTS13 💬 1件: Platelet activation 💬1件: 64 💬
20BAX930 or SHP655----1件: 64 💬
21BAX930 or SHP655 or TAK755----1件: 64 💬
22BCMA-CD19 CAR-T therapy----6件: 48, 49, 51, 53, 56, 64 💬
23Blood sampling----15件: 2, 3, 13, 14, 17, 46, 51, 64, 86, 96, 97, 98, 106, 162, 300 💬
24BMS-986413----2件: 63, 64 💬
25BMS-986414----2件: 63, 64 💬
26BORTEZOMIB1件: Bortezomib1件: Bortezomib 💬 1件: PSMB5 💬 8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬19件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 223, 228, 256, 283, 288, 331 💬
27Bortezomib Injection1件: Bortezomib1件: Bortezomib 💬 1件: PSMB5 💬 8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 64 💬
28CABLIVI----1件: 64 💬
29Cablivi®----1件: 64 💬
30Cablivi®Product Name: Cablivi®Product Code: ALX0081Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: CaplacizumabCAS Number: 915810-67-2Current Sponsor code: ALX0081Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factorConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 12.5-Trade Name: Cablivi®Product Name: Cablivi®Product Code: ALX0081Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: CaplacizumabCAS Number: 915810-67-2Current Sponsor code: ALX0081Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factorConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 12.5-----1件: 64 💬
31Caplacizumab1件: Caplacizumab1件: Caplacizumab 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬2件: 63, 64 💬
32Caplacizumab (ALX-0081)1件: Caplacizumab1件: Caplacizumab 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
33Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)1件: Caplacizumab1件: Caplacizumab 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
34Caplacizumab (an anti-von Willebrand Factor Nanobody)1件: Caplacizumab1件: Caplacizumab 💬 1件: VWF 💬 9件: Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
35Corticosteroid treatment (Methylprednisolone or prednisolone)2件: Methylprednisolone,
Prednisolone		3件: Methylprednisolone ,
Prednisolone ,
Methylprednisolone acetate 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 64 💬
36Corticosteroids----13件: 41, 46, 49, 63, 64, 97, 107, 113, 164, 222, 223, 296, 300 💬
37Cryosupernatant plasma----1件: 64 💬
38Cyclosporine1件: Cyclosporine1件: Cyclosporine 💬 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬 		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬39件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 67, 90, 95, 97, 107, 118, 162, 164, 222, 223, 226, 228, 234, 283, 284, 285, 302 💬
39Danazol1件: Danazol1件: Danazol 💬 3件: AR,
ESR1,
PGR 💬 		12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Estrogen signaling pathway, Hormone signaling, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬5件: 60, 63, 64, 65, 285 💬
40Desmopressin1件: Desmopressin2件: Desmopressin ,
Desmopressin acetate 💬 		2件: AVPR2,
F8 💬 		5件: Complement and coagulation cascades, Hormone signaling, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬8件: 6, 22, 64, 72, 75, 223, 225, 288 💬
41Desmopressin acetate2件: Acetate,
Desmopressin		2件: Desmopressin ,
Desmopressin acetate 💬 		2件: AVPR2,
F8 💬 		5件: Complement and coagulation cascades, Hormone signaling, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬2件: 64, 75 💬
42Dexamethasone1件: Dexamethasone3件: Dexamethasone ,
Dexamethasone sodium phosphate ,
Dexamethasone phosphate 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬29件: 13, 14, 16, 19, 28, 35, 46, 53, 63, 64, 65, 70, 71, 74, 75, 81, 84, 90, 96, 97, 162, 222, 223, 235, 257, 283, 296, 299, 331 💬
43Diagnostic Test: BlyS----1件: 64 💬
44Diagnostic Test: C5a----1件: 64 💬
45Diagnostic Test: evaluation of thrombus formation with Total Thrombus formation Analysis System (T-TAS)----1件: 64 💬
46Diagnostic Test: F1+2----1件: 64 💬
47Diagnostic Test: Factor VIII (FVIII)----1件: 64 💬
48Diagnostic Test: GFAP----1件: 64 💬
49Diagnostic Test: ICAM----1件: 64 💬
50Diagnostic Test: IL-1beta----1件: 64 💬
51Diagnostic Test: IL-1ß----1件: 64 💬
52Diagnostic Test: IL-6----1件: 64 💬
53Diagnostic Test: Microfluidic Flow Chamber----1件: 64 💬
54Diagnostic Test: Neutrophil elastase and myeloperoxidase (NETs) markers----1件: 64 💬
55Diagnostic Test: NFL----1件: 64 💬
56Diagnostic Test: Proteomic Analysis----1件: 64 💬
57Diagnostic Test: PTX3----1件: 64 💬
58Diagnostic Test: sCD40L----1件: 64 💬
59Diagnostic Test: soluble C5b-9----1件: 64 💬
60Diagnostic Test: sP-selectin----1件: 64 💬
61Diagnostic Test: VCAM----1件: 64 💬
62Diagnostic Test: VEGF-A----1件: 64 💬
63Diagnostic Test: Von Willebrand factor (VWF) antigen----1件: 64 💬
64Diagnostic Test: VWF multimers----1件: 64 💬
65Diagnostic Test: VWF-propeptide----1件: 64 💬
66Diagnostic Test: VWF:RCo----1件: 64 💬
67Efgartigimod1件: Efgartigimod alfa1件: Efgartigimod alfa 💬 --8件: 11, 14, 35, 36, 53, 63, 64, 300 💬
68Genetic: Whole exome sequencing - WES----1件: 64 💬
69Gold1件: Gold---71件: 2, 5, 6, 11, 13, 17, 19, 21, 22, 28, 34, 35, 46, 49, 50, 53, 54, 56, 57, 58, 60, 63, 64, 65, 66, 68, 71, 75, 76, 77, 79, 84, 85, 86, 88, 91, 93, 95, 96, 97, 98, 107, 113, 127, 137, 158, 162, 167, 171, 193, 206, 215, 218, 222, 223, 224, 226, 227, 228, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318, 331, 340 💬
70HMED-IdeS----2件: 64, 221 💬
71IDEC-C2B8, Ro 45-2294----1件: 64 💬
72IdeS----1件: 64 💬
73IdeS (0.25 mg/kg)----1件: 64 💬
74IdeS (0.50 mg/kg)----1件: 64 💬
75Immunosuppressive treatment (eg, rituximab)1件: Rituximab1件: Rituximab 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 64 💬
76Mabthera----20件: 11, 13, 35, 43, 44, 45, 46, 50, 51, 52, 53, 61, 63, 64, 65, 83, 162, 222, 223, 271 💬
77Magnesium1件: Magnesium---23件: 3, 6, 11, 13, 15, 46, 64, 70, 71, 93, 97, 113, 166, 225, 234, 235, 256, 284, 291, 296, 297, 298, 340 💬
78Methylprednisolone1件: Methylprednisolone2件: Methylprednisolone ,
Methylprednisolone acetate 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬51件: 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 111, 127, 145, 162, 164, 211, 222, 223, 224, 271, 283, 284, 285, 296, 300 💬
79Minirin----1件: 64 💬
80Nanobody directed towards the human A1 domain of von Willebrand factor----1件: 64 💬
81Octaplas----1件: 64 💬
82Octaplas infusion----1件: 64 💬
83Octaplas SD----1件: 64 💬
84OctaplasLG®----1件: 64 💬
85Octaplas®LG----1件: 64 💬
86Octostim----2件: 64, 288 💬
87OMS721----3件: 64, 66, 109 💬
88OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody----2件: 64, 109 💬
89OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody----2件: 64, 109 💬
90Other: Standard of Care----11件: 13, 49, 57, 64, 79, 85, 95, 96, 97, 245, 246 💬
91Plasma exchange----7件: 13, 43, 44, 64, 95, 171, 222 💬
92Plasma exchange (PE)----6件: 11, 13, 64, 66, 221, 223 💬
93Pooled Plasma (Human), Solvent/Detergent Treated----1件: 64 💬
94PREDNISOLONE1件: Prednisolone1件: Prednisolone 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬48件: 3, 11, 13, 14, 18, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 57, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 111, 113, 145, 162, 222, 223, 251, 269, 271, 296, 299, 300 💬
95Prednisone1件: Prednisone1件: Prednisone 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬58件: 2, 11, 13, 14, 18, 19, 26, 28, 35, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 53, 60, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 90, 93, 95, 96, 97, 113, 127, 145, 162, 164, 205, 222, 223, 224, 228, 251, 269, 283, 284, 285, 288, 299, 300, 303, 307, 331 💬
96Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13----1件: 64 💬
97Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1----1件: 64 💬
98Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs----1件: 64 💬
99Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13----1件: 64 💬
100Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13)1件: Apadamtase alfa2件: Apadamtase alfa ,
Apadamtase alfa and cinaxadamtase alfa 💬 		1件: ADAMTS13 💬 1件: Platelet activation 💬1件: 64 💬
101Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13) Product Code: TAK-755Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: Apadamtase alfaCurrent Sponsor code: TAK-755Other descriptive name: BAX930 - RECOMBINANT HUMAN ADAMTS13Concentration unit: IU international unit(s)Concentration type: equalConcentration number: 1500-Pharmaceutical form of the placebo: Powder and solution for solution for injectionRoute of administration of the placebo: Intravenous use----1件: 64 💬
102Recombinant ADAMTS13----1件: 64 💬
103RITUXIMAB1件: Rituximab1件: Rituximab 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬54件: 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 88, 93, 94, 96, 97, 162, 172, 222, 223, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
104Romiplostim1件: Romiplostim1件: Romiplostim 💬 1件: MPL 💬 3件: Cytokine-cytokine receptor interaction, Hormone signaling, JAK-STAT signaling pathway 💬4件: 60, 63, 64, 65 💬
105SHP 655 (BAX 930)----1件: 64 💬
106SHP655----1件: 64 💬
107Standard of Care----18件: 6, 13, 49, 51, 57, 58, 63, 64, 79, 84, 96, 97, 113, 171, 223, 228, 240, 291 💬
108Standard Plasma----1件: 64 💬
109Sulfate, Magnesium1件: Magnesium---1件: 64 💬
110TAK-755----1件: 64 💬
111TAK-755 or BAX930 or SHP655----1件: 64 💬
112TAK-755 orBAX930 or SHP655----1件: 64 💬
113TGD001----1件: 64 💬
114Uniplas----1件: 64 💬
115Water1件: Water1件: Water 💬 --36件: 2, 3, 5, 6, 13, 17, 19, 22, 35, 46, 49, 51, 53, 56, 57, 62, 63, 64, 65, 66, 67, 70, 72, 85, 86, 96, 97, 206, 215, 225, 226, 230, 240, 274, 278, 299 💬